Trastuzumab versus MYL-1401O (a proposed trastuzumab biosimilar) in a phase I bioequivalence study: In vivo and in vitro immunomodulation.

被引：0

作者：

Audran, Ra Agine

Chtioui, Haithem

Thierry, Anne-Christine

Mayor, Carole

Vallotton, Laure

Dao, Kim

Rothuizen, Laura

Maghraoui, Ali

Pennella, Eduardo J.

Brunner-Ferber, Francoise

Buclin, Thierry

Spertini, Francois

机构：

[1] CHU Vaudois, Univ Hosp, Div Immunol & Allergy, Lausanne, Switzerland

[2] CHU Vaudois, Univ Hosp, Div Clin Pharmacol, Lausanne, Switzerland

[3] CHU Vaudois, Univ Hosp, Div Immunol & Allergy, Lausanne, Switzerland

[4] CHU Vaudois, Univ Hosp, Div Clin Pharmacol, Lausanne, Switzerland

[5] Mylan, Canonsburg, PA USA

[6] Brunner Naga, Pfaeffikon, Switzerland

来源：

关键词：

D O I：

10.1200/JCO.2017.35.7_suppl.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1